{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:48:41Z","timestamp":1792072121466,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["517063424"],"award-info":[{"award-number":["517063424"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Summary\u00a0<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>This study explored whether Romosozumab, an anti-sclerostin antibody, can improve bone quality in women with Osteogenesis imperfecta. After 12 months, spinal areal bone mineral density increased, showing a beneficial treatment effect, although changes in hip bone density and bone structure were less pronounced than in women with severe osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Osteogenesis imperfecta (OI) is the most common hereditary bone disorder, characterized by increased bone fragility and impaired bone quality, but pharmacological treatment is limited. Ongoing clinical trials investigate monoclonal anti-sclerostin antibodies for OI patients, offering new hope for reducing bone fragility by increasing bone mass.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Postmenopausal women with either OI (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095) or severe osteoporosis (OPO,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910) receiving Romosozumab monthly (210\u00a0mg\u00a0s.c.) for 12\u00a0months were analyzed retrospectively. Clinical assessments were performed at baseline, after 6\u00a0months, and after 12\u00a0months. Bone mass and structure were evaluated at baseline and after 12\u00a0months of treatment. In addition, serum and urine markers of bone turnover were analyzed at each time point.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age of the participants was 53.6\u2009\u00b1\u20098.9\u00a0years for OI patients and 57.2\u2009\u00b1\u20095.8\u00a0years for OPO patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.444). After 12\u00a0months of Romosozumab treatment, spinal aBMD and osteocalcin increased significantly in OI patients, indicating an anabolic response. HR-pQCT analysis revealed no statistically significant microstructural changes in patients with OI, although trends and moderate effect sizes suggested potential improvements. In patients with OPO, we observed a more pronounced response of bone turnover markers with greater aBMD gains at both the spine and femur, as well as significant improvements in bone microstructure, particularly at the tibia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Romosozumab treatment in postmenopausal women with OI resulted in a significant increase in spinal aBMD, though the effect on hip aBMD and peripheral bone microstructure was limited in contrast to postmenopausal osteoporosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-026-01744-3","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T12:35:09Z","timestamp":1784378109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Romosozumab in postmenopausal women with classical Osteogenesis imperfecta"],"prefix":"10.1007","volume":"21","author":[{"given":"Mikolaj","family":"Bartosik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Windels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix N.","family":"von Brackel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Amling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Oheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"1744_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.52","volume":"3","author":"JC Marini","year":"2017","unstructured":"Marini JC, Forlino A, B\u00e4chinger HP et al (2017) Osteogenesis imperfecta. Nat Rev Dis Primers 3:17052. https:\/\/doi.org\/10.1038\/nrdp.2017.52","journal-title":"Nat Rev Dis Primers"},{"key":"1744_CR2","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","volume":"164a","author":"FS Van Dijk","year":"2014","unstructured":"Van Dijk FS, Sillence DO (2014) Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A 164a:1470\u20131481. https:\/\/doi.org\/10.1002\/ajmg.a.36545","journal-title":"Am J Med Genet A"},{"key":"1744_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101\u2013116. https:\/\/doi.org\/10.1136\/jmg.16.2.101","journal-title":"J Med Genet"},{"key":"1744_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00223-001-1055-5","volume":"72","author":"JR Shapiro","year":"2003","unstructured":"Shapiro JR, McCarthy EF, Rossiter K et al (2003) The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int 72:103\u2013112. https:\/\/doi.org\/10.1007\/s00223-001-1055-5","journal-title":"Calcif Tissue Int"},{"key":"1744_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/jci71101","volume":"124","author":"ES Orwoll","year":"2014","unstructured":"Orwoll ES, Shapiro J, Veith S et al (2014) Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 124:491\u2013498. https:\/\/doi.org\/10.1172\/jci71101","journal-title":"J Clin Invest"},{"key":"1744_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","volume":"93","author":"D Gatti","year":"2013","unstructured":"Gatti D, Rossini M, Viapiana O et al (2013) Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int 93:448\u2013452. https:\/\/doi.org\/10.1007\/s00223-013-9770-2","journal-title":"Calcif Tissue Int"},{"key":"1744_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.11138\/ccmbm\/2017.14.1.153","volume":"14","author":"PT Leali","year":"2017","unstructured":"Leali PT, Balsano M, Maestretti G et al (2017) Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study. Clin Cases Miner Bone Metab 14:153\u2013156. https:\/\/doi.org\/10.11138\/ccmbm\/2017.14.1.153","journal-title":"Clin Cases Miner Bone Metab"},{"key":"1744_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025900","volume":"6","author":"AR Wijenayaka","year":"2011","unstructured":"Wijenayaka AR, Kogawa M, Lim HP et al (2011) Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 6:e25900. https:\/\/doi.org\/10.1371\/journal.pone.0025900","journal-title":"PLoS ONE"},{"key":"1744_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00774-020-01176-0","volume":"39","author":"S Tanaka","year":"2021","unstructured":"Tanaka S, Matsumoto T (2021) Sclerostin: from bench to bedside. J Bone Miner Metab 39:332\u2013340. https:\/\/doi.org\/10.1007\/s00774-020-01176-0","journal-title":"J Bone Miner Metab"},{"key":"1744_CR10","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s00198-015-3127-9","volume":"26","author":"S Pelletier","year":"2015","unstructured":"Pelletier S, Confavreux CB, Haesebaert J et al (2015) Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int 26:2165\u20132174. https:\/\/doi.org\/10.1007\/s00198-015-3127-9","journal-title":"Osteoporos Int"},{"key":"1744_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326. https:\/\/doi.org\/10.1002\/jbmr.173","journal-title":"J Bone Miner Res"},{"key":"1744_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"key":"1744_CR13","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"1744_CR14","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/jbmr.3439","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S et al (2018) Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res 33:1407\u20131416. https:\/\/doi.org\/10.1002\/jbmr.3439","journal-title":"J Bone Miner Res"},{"key":"1744_CR15","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/jbmr\/zjae112","volume":"39","author":"FH Glorieux","year":"2024","unstructured":"Glorieux FH, Langdahl B, Chapurlat R et al (2024) Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study. J Bone Miner Res 39:1215\u20131228. https:\/\/doi.org\/10.1093\/jbmr\/zjae112","journal-title":"J Bone Miner Res"},{"key":"1744_CR16","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/jbmr.3143","volume":"32","author":"FH Glorieux","year":"2017","unstructured":"Glorieux FH, Devogelaer J-P, Durigova M et al (2017) BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial. J Bone Miner Res 32:1496\u20131504. https:\/\/doi.org\/10.1002\/jbmr.3143","journal-title":"J Bone Miner Res"},{"key":"1744_CR17","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS et al (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359\u20132381. https:\/\/doi.org\/10.1007\/s00198-014-2794-2","journal-title":"Osteoporos Int"},{"key":"1744_CR18","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00198-020-05438-5","volume":"31","author":"DE Whittier","year":"2020","unstructured":"Whittier DE, Boyd SK, Burghardt AJ et al (2020) Guidelines for the assessment of bone density and microarchitecture in vivo using high-resolution peripheral quantitative computed tomography. Osteoporos Int 31:1607\u20131627. https:\/\/doi.org\/10.1007\/s00198-020-05438-5","journal-title":"Osteoporos Int"},{"key":"1744_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-023-01143-7","author":"M Bartosik","year":"2023","unstructured":"Bartosik M, Simon A, Strahl A et al (2023) Comparison of motion grading in 1,000 patients by first- and second-generation HR-pQCT: a propensity score matched cohort study. Calcif Tissue Int. https:\/\/doi.org\/10.1007\/s00223-023-01143-7","journal-title":"Calcif Tissue Int"},{"key":"1744_CR20","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.bone.2011.03.755","volume":"48","author":"M Sode","year":"2011","unstructured":"Sode M, Burghardt AJ, Pialat JB, Link TM, Majumdar S (2011) Quantitative characterization of subject motion in HR-pQCT images of the distal radius and tibia. Bone 48:1291\u20131297. https:\/\/doi.org\/10.1016\/j.bone.2011.03.755","journal-title":"Bone"},{"key":"1744_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00223-013-9808-5","volume":"94","author":"S Hansen","year":"2014","unstructured":"Hansen S, Shanbhogue V, Folkestad L, Nielsen MM, Brixen K (2014) Bone microarchitecture and estimated strength in 499 adult Danish women and men: a cross-sectional, population-based high-resolution peripheral quantitative computed tomographic study on peak bone structure. Calcif Tissue Int 94:269\u2013281. https:\/\/doi.org\/10.1007\/s00223-013-9808-5","journal-title":"Calcif Tissue Int"},{"key":"1744_CR22","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/jbmr.4114","volume":"35","author":"DE Whittier","year":"2020","unstructured":"Whittier DE, Burt LA, Hanley DA, Boyd SK (2020) Sex- and site-specific reference data for bone microarchitecture in adults measured using second-generation HR-pQCT. J Bone Miner Res 35:2151\u20132158. https:\/\/doi.org\/10.1002\/jbmr.4114","journal-title":"J Bone Miner Res"},{"key":"1744_CR23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/ejendo\/lvaf211","volume":"193","author":"SE Lee","year":"2025","unstructured":"Lee SE, Ahn SH, Kim BJ et al (2025) Efficacy comparison of 6-month romosozumab plus denosumab versus 12-month romosozumab in Koreans. Eur J Endocrinol 193:627\u2013634. https:\/\/doi.org\/10.1093\/ejendo\/lvaf211","journal-title":"Eur J Endocrinol"},{"key":"1744_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07722-8","author":"G Adami","year":"2025","unstructured":"Adami G, Bartezaghi M, Montanari F et al (2025) Romosozumab early experience in female patients with severe osteoporosis in an Italian real-world setting, the ROMEO study. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-025-07722-8","journal-title":"Osteoporos Int"},{"key":"1744_CR25","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00198-020-05815-0","volume":"32","author":"EV McCloskey","year":"2021","unstructured":"McCloskey EV, Johansson H, Harvey NC et al (2021) Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporos Int 32:1601\u20131608. https:\/\/doi.org\/10.1007\/s00198-020-05815-0","journal-title":"Osteoporos Int"},{"key":"1744_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00774-023-01477-0","volume":"42","author":"A Miyauchi","year":"2024","unstructured":"Miyauchi A, Hamaya E, Shimauchi J, Yoshinaga Y, Nishi K (2024) Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study. J Bone Miner Metab 42:77\u201389. https:\/\/doi.org\/10.1007\/s00774-023-01477-0","journal-title":"J Bone Miner Metab"},{"key":"1744_CR27","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/jbmr.1592","volume":"27","author":"L Folkestad","year":"2012","unstructured":"Folkestad L, Hald JD, Hansen S et al (2012) Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT. J Bone Miner Res 27:1405\u20131412. https:\/\/doi.org\/10.1002\/jbmr.1592","journal-title":"J Bone Miner Res"},{"key":"1744_CR28","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1007\/s00198-016-3653-0","volume":"27","author":"JD Hald","year":"2016","unstructured":"Hald JD, Folkestad L, Harsl\u00f8f T et al (2016) Skeletal phenotypes in adult patients with osteogenesis imperfecta-correlations with COL1A1\/COL1A2 genotype and collagen structure. Osteoporos Int 27:3331\u20133341. https:\/\/doi.org\/10.1007\/s00198-016-3653-0","journal-title":"Osteoporos Int"},{"key":"1744_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07774-w","author":"M Bartosik","year":"2025","unstructured":"Bartosik M, Prengel M, Delsmann J et al (2025) Genotype-based comparison of bone microstructure in adult patients with classical osteogenesis imperfecta. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-025-07774-w","journal-title":"Osteoporos Int"},{"key":"1744_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.aace.2023.10.002","volume":"9","author":"A Dattagupta","year":"2023","unstructured":"Dattagupta A, Petak S (2023) Osteoporosis improved by romosozumab therapy in a patient with type I osteogenesis imperfecta. AACE Clin Case Rep 9:209\u2013212. https:\/\/doi.org\/10.1016\/j.aace.2023.10.002","journal-title":"AACE Clin Case Rep"},{"key":"1744_CR31","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00198-024-07089-2","volume":"35","author":"T Kusakabe","year":"2024","unstructured":"Kusakabe T, Ishihara Y, Kitamura T et al (2024) Beneficial effects of romosozumab on bone mineral density and trabecular bone score assessed by dual-energy X-ray absorptiometry in a family with osteogenesis imperfecta. Osteoporos Int 35:1303\u20131304. https:\/\/doi.org\/10.1007\/s00198-024-07089-2","journal-title":"Osteoporos Int"},{"key":"1744_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/mrcr\/rxab018","volume":"6","author":"M Uehara","year":"2022","unstructured":"Uehara M, Nakamura Y, Nakano M et al (2022) Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: a case report. Mod Rheumatol Case Rep 6:128\u2013133. https:\/\/doi.org\/10.1093\/mrcr\/rxab018","journal-title":"Mod Rheumatol Case Rep"},{"key":"1744_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117701","volume":"202","author":"E Gielen","year":"2026","unstructured":"Gielen E, Amini N, Coppens D et al (2026) Bone mineral density response to romosozumab in post-menopausal women: a prospective observational real-world study. Bone 202:117701. https:\/\/doi.org\/10.1016\/j.bone.2025.117701","journal-title":"Bone"},{"key":"1744_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2026.6889","author":"JD Hald","year":"2026","unstructured":"Hald JD, Weir CJ, Keerie C et al (2026) Teriparatide plus zoledronic acid for osteogenesis imperfecta: a randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2026.6889","journal-title":"JAMA"},{"key":"1744_CR35","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s00774-015-0708-9","volume":"34","author":"AK Amstrup","year":"2016","unstructured":"Amstrup AK, Jakobsen NF, Moser E et al (2016) Association between bone indices assessed by DXA, HR-pQCT and QCT scans in post-menopausal women. J Bone Miner Metab 34:638\u2013645. https:\/\/doi.org\/10.1007\/s00774-015-0708-9","journal-title":"J Bone Miner Metab"},{"key":"1744_CR36","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/jbmr.3901","volume":"35","author":"N Mikolajewicz","year":"2020","unstructured":"Mikolajewicz N, Bishop N, Burghardt AJ et al (2020) HR-pQCT measures of bone microarchitecture predict fracture: systematic review and meta-analysis. J Bone Miner Res 35:446\u2013459. https:\/\/doi.org\/10.1002\/jbmr.3901","journal-title":"J Bone Miner Res"},{"key":"1744_CR37","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00223-018-0447-8","volume":"103","author":"T Rolvien","year":"2018","unstructured":"Rolvien T, St\u00fcrznickel J, Schmidt FN et al (2018) Comparison of bone microarchitecture between adult osteogenesis imperfecta and early-onset osteoporosis. Calcif Tissue Int 103:512\u2013521. https:\/\/doi.org\/10.1007\/s00223-018-0447-8","journal-title":"Calcif Tissue Int"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01744-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01744-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01744-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T12:35:10Z","timestamp":1784378110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-026-01744-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1744"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01744-3","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was performed in accordance with the local ethical guidelines (PV5364 and 2023\u2013101124-BO-ff) and the Declaration of Helsinki. All patients gave written informed consent for retrospective analysis of the derived data from clinical routine measurements during their visit at our outpatients\u2019 clinic.","order":1,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MA declares that there is no conflict of interest. MB received travel grant from Fresenius. OW received a travel grant from Inozyme. RO has served as a speaker and advisory board member for Kyowa Kirin, Inozyme, Ipsen, Mereo, Pharmacosmos and UCB and has received institutional research grants from Kyowa Kirin, UCB and Inozyme.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"100"}}